U.S. Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
79.9700+0.14 (+0.18%)
At close: 4:00PM EDT

79.6751 -0.29 (-0.37%)
After hours: 4:11PM EDT

People also watch
BMRNACORSGENACADALXN
Full screen
Previous Close79.8300
Open80.5000
Bid76.0100 x 100
Ask81.6900 x 200
Day's Range78.6900 - 80.8100
52 Week Range31.3800 - 86.9200
Volume1,014,956
Avg. Volume1,035,320
Market Cap7.32B
Beta3.47
PE Ratio (TTM)-16.55
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com10 hours ago

    [$$] Alnylam Selloff Looks Like an Overreaction

    Alnylam Pharmaceuticals (ALNY:Nasdaq) By Credit Suisse ($85.21, June 26, 2017) We are raising our target price on Alnylam Pharmaceuticals to $96 from $90 as we increased our probability of success from 40% to 60% in porphyria. At 100% success this adds $12 a share to our model (due to high operating leverage and modeling of fixed costs for the research platform). At 0% success to porphyria our discounted-cash-flow model is $18 a share lower at $78 a share.

  • 5 Best Biotech Stocks of 2017 So Far
    Motley Fool3 days ago

    5 Best Biotech Stocks of 2017 So Far

    How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far.

  • Why is Alnylam's (ALNY) Stock Close to 100% this Year?
    Zacks13 days ago

    Why is Alnylam's (ALNY) Stock Close to 100% this Year?

    Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.